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Mas receptorIn this study we investigated the effects of genetic deletion of the Angiotensin-(1-7) receptor Mas or the Angio-
tensin II receptor AT2 on the expression of speciﬁc extracellular matrix (ECM) proteins in atria, right ventricles
and atrioventricular (AV) valves of neonatal and adult mice. Quantiﬁcation of collagen types I, III and VI and ﬁ-
bronectin was performed using immunoﬂuorescence-labeling and confocal microscopy. Picrosirius red staining
was used for the histological assessment of the overall collagen distribution pattern. ECM proteins, metallopro-
teinases (MMP), ERK1/2 and p38 levels were quantiﬁed by western blot analysis. Gelatin zymography was used
to evaluate the activity ofMMP-2 andMMP-9.We observed that the relative levels of collagen types I and III and
ﬁbronectin are signiﬁcantly higher in both the right ventricle and AV valves of neonatal Mas−/− mouse hearts
(e.g., collagen type I: 85.28±6.66 vs 43.50±4.41 arbitrary units in the right ventricles of Mas+/+ mice). Con-
versely, the level of collagen type VI was lower in the right ventricle and AV valves of Mas−/− mice. Adult
Mas−/−mouse hearts presented similar patterns as observed in neonates. No signiﬁcant differences in ECM pro-
tein level were detected in atria. Likewise, no changes in ECM levels were observed in AT2 knockout mouse
hearts. Although deletion of Mas induced a signiﬁcant reduction in the level of the active form of MMP-2 in ne-
onate hearts and a reduction of both MMP-2 and MMP-9 in adult Mas−/−mice, no signiﬁcant differences were
observed inMMPenzymatic activitieswhen compared to controls. The levels of the active, phosphorylated forms
of ERK1/2 and p38 were higher in hearts of both neonatal and adult Mas−/−mice. These observations suggest
thatMas is involved in the selective expression of speciﬁc ECMproteinswithin both the ventricularmyocardium
and AV valves. The changes in the ECM proﬁle may alter the connective tissue framework and contribute to the
decreased cardiac performance observed in Mas−/−mice.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
The extracellular matrix (ECM) has been described as a supportive
scaffold which is important in both formation and maintenance of tis-
sues. In the heart, ECM forms an elaborate, stress-tolerant network,
interconnecting myocytes to each other and myocytes to capillaries
within the ventricular wall [1]. Interactions between cells and the
surrounding ECM play critical roles in a number of cellular processes,
including migration, proliferation, differentiation and survival. Thegy, Av. Antônio Carlos, 6627,
el.: +55 31 3409 2806; fax:
a), kitten@icb.ufmg.br
vier OA license.interstitial network within the myocardium is composed predomi-
nantly of ﬁbrillar collagen types I and III [2]. Cardiac ﬁbrillar collagen
provides structural scaffolding for cardiomyocytes and coronary ves-
sels and imparts cardiac tissue with physical properties that include
stiffness and resistance to deformation [2,3]. It is now clear that the
ECM is a dynamic structure whose organization and composition
are known to modulate various cellular processes. Events that alter
the molecular composition of the ECM, or the structural organization
of ECM components, can induce profound changes in cellular func-
tions [4]. Excessive deposition of collagen is thought to contribute to
abnormal stiffness and function of the ventricular myocardium [5].
In many cases these changes are associated with activation of humor-
al systems such as the renin–angiotensin system (RAS) [6].
Components of the circulating and local RAS are closely involved
in the development of myocardial ﬁbrosis in hypertensive heart
31E. Gava et al. / Regulatory Peptides 175 (2012) 30–42disease and chronic heart failure. The classical effector of this system,
the octapeptide Angiotensin (Ang) II, exerts its effects through specif-
ic Ang II receptor isoforms, AT1 and AT2. Ang II binds AT1 receptor and
stimulates synthesis and deposition of collagen in a dose-dependent
manner and suppresses the activity of matrix metalloproteinase
(MMP) 1, an enzyme which plays an important role in interstitial
collagen degradation [7]. On the other hand, accumulating lines of
evidence support the broad view that Ang II can bind to the AT2 re-
ceptor and induce growth suppression [8]. Conversely, Ang-(1-7), a
biologically active member of the RAS and an endogenous ligand
for the G protein-coupled Mas receptor [9], has been suggested to
act as an antiproliferative [10–14] and anti-ﬁbrotic peptide [13,14].
Ang-(1-7) inhibits growth of cardiomyocytes through Mas-mediatedA
C
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Mas+/+
Fig. 1. Immunoﬂuorescent localization of Mas in hearts. Mas is present in tricuspid valve
tricuspid valve (B), right ventricle (D) and atria (F) of adult Mas−/− mouse hearts. No immu
from the incubation procedure (not shown). Insets are low magniﬁcation views of the tissue aevents, which include ERK1/2 activities [13]. In addition, Ang-(1-7)
and its analog AVE 0991 have been shown to attenuate the develop-
ment of heart failure after myocardial infarction, a ﬁnding that suggests
a role for this peptide in cardiac remodeling [15,16]. In keeping with
these data, AVE 0991 also prevented isoproterenol-induced cardiac
remodeling [17]. These effects are apparently independent of changes
in blood pressure sinceGrobe and colleagues [18,19] have demonstrated
that the anti-ﬁbrotic and anti-hypertrophic actions of Ang-(1-7) are still
observed in Ang II-infused [19] or in DOCA-salt hypertensive rats [18].
Overexpression of the main Ang-(1-7)-forming enzyme, angiotensin-
converting enzyme 2 (ACE2), in a rat model of myocardial infarction
protected the infarcted myocardium against pathological remodel-
ing and cardiac systolic dysfunction [20]. The anti-ﬁbrotic and anti-B
D
F
Mas -/-
(A), right ventricle (C) and atria (E) of adult Mas+/+ mouse hearts but absent in the
nostaining was detected in any of the samples when the primary antibody was omitted
reas analyzed. Representative ﬁgures of three different animals. Bar=50 μm.
M
as
+
/+
M
as
-
/-
Col I Col III FN Col VI
M
as
+
/+
M
as
-
/-
R
ig
ht
 v
en
tri
cl
e
Tr
ic
us
pi
d 
va
lv
e
0
25
50
75
100
125
Col I Col III FN Col VI
* *
*
*
R
el
at
iv
e 
Fl
uo
re
sc
en
cy
In
te
ns
ity
 (A
U)
0
25
50
75
100
125
Col I Col III FN Col VI
* * *
*
R
el
at
iv
e 
Fl
uo
re
sc
en
cy
In
te
ns
ity
 (A
U)
Right ventricle 
0
25
50
75
100
125
150
Col I Col III FN Col VI
*
* *
*
R
el
at
iv
e 
Fl
uo
re
sc
en
cy
In
te
ns
ity
 (A
U)
0
25
50
75
Col I Col III FN Col VI
R
el
at
iv
e 
Fl
uo
re
sc
en
cy
In
te
ns
ity
 (A
U)
Mas +/+; n=6 Mas -/-; n=6
Tricuspid valveMitral valve
Atria
A
B
Fig. 2. Immunoﬂuorescent localization of collagen types I, III and VI and ﬁbronectin in the right ventricle and tricuspid valve of neonatal Mas+/+ and Mas−/−mouse hearts (A). The
inset shows the level of immunostaining obtained when the primary antibody was omitted from the incubation procedure. Quantiﬁcation of ECM proteins in the right ventricle, AV
valves and atria of neonatal Mas+/+ and Mas−/− mice (B). Values are expressed as arbitrary units (AU). Data are shown as mean±SEM. *pb0.05. Bar=50 μm.
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33E. Gava et al. / Regulatory Peptides 175 (2012) 30–42hypertrophic actions of ACE2/Ang-(1-7) were also observed in animals
(rats and mice) with pulmonary hypertension induced by monocrota-
line [21,22] and in rats with pulmonary ﬁbrosis caused by bleomycin
treatment [23]. Recently, we have shown that deletion of the Ang-(1-
7) receptor Mas markedly decreases cardiac function in adult mice in
part due to changes in collagen levels to a pro-ﬁbrotic proﬁle, i.e.
an increase of collagen types I and III and ﬁbronectin and a decrease
of collagen type VI in left ventricles [24]. However, it is unknown
whether these alterations in ECM extend to other regions of hearts
from neonatal and adult mice, such as the right ventricle, atria and
atrioventricular (AV) valves. Thus, in the current study we evaluated
the presence of Mas in the right ventricle, atria and AV valves of neo-
natal and adult mice and checked if its deletion leads to alterations
in ECM deposition in these regions. In addition, we investigated
the effects of deletion of the AT2 receptor on the expression of
ECM proteins in adult mouse hearts, since in certain circumstances
AT2 receptors appear to be involved in the Ang-(1-7) effects.2. Material and methods
2.1. Mas knockout mice and AT2 knockout mice
Male wild-type (Mas+/+, AT2+/y) and Mas and AT2 knockout
(Mas−/−, AT2−/y) C57BL/6 mice (adult mice: 8–12 weeks old; neonate
mice: 1 day old) were obtained from the transgenic animal facilities
of the Laboratory of Hypertension, Federal University of Minas Gerais,
Brazil. All animal procedures were performed in accordance with
institutional guidelines (Federal University of Minas Gerais, Brazil).
Genotypes were conﬁrmed by PCR analysis.Mas+/+ Mas-/-
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Fig. 3.Western blotting analysis of the levels of collagen types I (A), III (B) and VI (C) and ﬁb
normalized using GAPDH. Data are shown as the SEM. *pb0.05.2.2. Immunostaining and confocal microscopy
Immunoﬂuorescence-labeling and quantitative confocal microscopy
were used to investigate the distribution and quantity of Mas, collagen
types I, III and VI and ﬁbronectin present in Mas+/+, Mas−/−, AT2+/y and
AT2−/y mice hearts. Hearts were collected fromMas+/+ andMas−/− neo-
natal (n=6) andadult (n=6)malemice and fromAT2+/y andAT2−/y adult
(n=4)male mice, washed in phosphate-buffered saline (PBS) and cryo-
ﬁxed in a−80 °C solution of 80% methanol and 20% dimethyl sulfox-
ide. After 5–7 days of freeze-substitution, samples were embedded in
parafﬁn following standard methods [24]. Five micrometer thick sec-
tions were mounted on slides, deparafﬁnized, rehydrated and then
incubated in blocking solution (1% BSA and 0.1% Tween 20 in PBS)
at room temperature for 1 h. Sections were incubated overnight at
4 °C with one of the following primary antibodies: rabbit anti-
human Mas (1:100, Abcam, Cambridge, MA), rabbit anti-human col-
lagen type I (1:400, Rockland Immunochemicals Inc., Gilbertsville,
PA), rabbit anti-human collagen type III (1:400, Rockland Immuno-
chemicals Inc., Gilbertsville, PA), rabbit anti-human collagen type VI
(1:600, Research Diagnostics Inc., Acton, MA) or rabbit anti-human
ﬁbronectin (1:800, Rockland Immunochemicals Inc., Gilbertsville,
PA). After 4–5 rinses in PBS, donkey anti-rabbit IgG conjugated with
Cy3 (1:500, Jackson ImmunoResearch Laboratories, West Grove, PA)
was added for 1 h in the dark at room temperature. Following washes
with PBS, sections were mounted and viewed with a laser scanning
confocal microscope (Zeiss 510Meta). Optimal confocal settings
(aperture, gain and laser power) were determined at the beginning
of each imaging session and then held constant during the analysis
of all the samples. Nuclei were labeled with 4′6-diamidino-2-
phenylindole dihydrochloride (DAPI) (Molecular Probes, Carlsbad,Mas+/+ Mas-/-
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Fig. 4. Immunoﬂuorescent localization of collagen types I, III and VI and ﬁbronectin in the right ventricle and tricuspid valve of adult Mas+/+ and Mas−/−mouse hearts (A). Quan-
tiﬁcation of ECM proteins in the right ventricle, AV valves and atria of adult Mas+/+ and Mas−/− mice (B). Values are expressed as arbitrary units (AU). Data are shown as
mean±SEM. *pb0.05. Bar=50 μm.
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Table 1
Echocardiographic analysis of Mas+/+ and Mas−/− mice.
Parameter Mas+/+ (n=5) Mas−/− (n=5)
Cardiac output (mL/min) 18.76±1.30 16.80±1.05
LV internal dimension at diastole (mm) 3.72±0.14 4.20±0.06⁎
LV internal dimension at systole (mm) 2.46±0.14 3.32±0.03⁎
LV ejection fraction (%) 63.48±2.82 42.90±1.26⁎
LV fractional shortening (%) 34.07±2.06 20.93±0.74⁎
LV systolic volume (μL) 37.37±2.70 33.85±2.05
End diastolic LV volume (μL) 59.45±5.04 78.72±2.80⁎
End systolic LV volume (μL) 22.08±2.97 44.87±1.24⁎
Heart rate (bpm) 492.60±25.70 487.80±20.70
RV fractional area change (FAC) (%) 57.58±1.20 38.69±2.30⁎
Data are reported asmean±SEM. Statistical analyses were performed using Student's
t test. LV: left ventricle; RV: right ventricle. *pb0.05.
35E. Gava et al. / Regulatory Peptides 175 (2012) 30–42CA). For quantitative analysis of collagens I, III and VI and ﬁbronectin,
we used the ImageTool 2.0 image analysis program (http://ddsdx.
uthscsa.edu/dig/itdesc.html) to measure the ﬂuorescence intensity
in images randomly selected from the right ventricle, AV valves
and atria of Mas+/+ and Mas−/− mice and from the right and left
ventricles of AT2+/y and AT2−/y mice. Images were captured at 12 bit
and analyzed in the gray scale range of 0 to 255. Fluorescence inten-
sity was measured as an average of the area (i.e. the sum of gray
values of all pixels divided by the number of pixels in the area) and
values recorded as arbitrary units (AU). Background ﬂuorescence
was measured and subtracted from the region of interest.
2.3. Histological analysis
Picrosirius red staining was used for histological analysis of total
collagen content in tricuspid valves of neonatal and adult Mas−/−
and Mas+/+ mice and right ventricles of adult Mas−/− and Mas+/+
mice (n=5 per group). Samples were prepared as described above,
sectioned at a thickness of 5 μm, stained with picrosirius red (direct
red 80) [25] and then analyzed at 10× magniﬁcation using polarizing
ﬁlters adapted onto a conventional light microscope.
2.4. Western blotting
Right ventricles from adult mice (n=2–4) and whole hearts from
neonatemice (n=2–8)were collected and homogenized in lysis buffer
containing 1% Nonidet P40, 0.5% sodium deoxycholate, 0.1% SDS,
0.1 mmol/L PMSF, 1 mmol/L pepstatin A, 1 mmol/L leupeptin, and
1 mmol/L aprotinin. Forty micrograms of protein from each sample
were separated by electrophoresis on a 10% polyacrylamide gel and
transferred to nitrocellulose membranes. Non-speciﬁc binding wasMas+/+ Mas-/-
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Fig. 5. Western blotting analysis of the levels of collagen types I (A), III (B) and VI (C) and ﬁ
normalized using GAPDH. Data are shown as the SEM. *pb0.05 and **pb0.001.blocked by incubation in 5%milk and 0.1% Tween 20 in Tris-buffered sa-
line. Membranes were probed with speciﬁc primary antibodies: anti-
collagen type I (1:500, Rockland Immunochemicals Inc., Gilbertsville,
PA), anti-collagen type III (1:3000, Rockland Immunochemicals Inc.,
Gilbertsville, PA), anti-collagen type VI (1:500, Research Diagnostics
Inc., Acton, MA), anti-ﬁbronectin (1:5000, Rockland Immunochem-
icals Inc., Gilbertsville, PA), anti-p38MAPK (1:1000, Cell Signaling
Technology Inc., Danvers, MA), anti-ERK1/2 (1:1000, Cell Signaling
Technology Inc., Danvers, MA), anti-MMP-2 (1:500, Chemicon Interna-
tional, Billerica, MA), anti-MMP-9 (1:500, Chemicon International, Biller-
ica, MA) or anti-GAPDH (1:5000, Santa Cruz Biotechnology, Santa Cruz,
CA) followed by incubation with enzyme-labeled secondary antibodies.
The membrane was incubated in chemiluminescent substrate then ex-
posed to ﬁlm. Immunoreactive bands were quantiﬁed by densitometry
using GAPDH, total p38 or total ERK1/2 as a normalization control.Mas+/+ Mas-/-
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
2.00
*
n=2 n=2
Fi
br
o
n
ec
tin
 / 
G
AP
DH
Fibronectin
GAPDH
D
Mas+/+ Mas-/-
0.00
0.25
0.50
0.75
1.00
1.25
1.50
**
Co
lla
ge
n
 
III
 / 
GA
PD
H
n=2 n=2
Collagen III
GAPDH
B
bronectin (D) in hearts of adult Mas+/+ and Mas−/− mice. Densitometry values were
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Right ventricles from adult mice (n=3) and whole hearts from
neonate mice (n=3–8) were homogenized in 50 mmol/L Tris–HCl
pH 7.4, 0.2 mol/L NaCl, 0.1% Triton, 10 mmol/L CaCl2 and 1% Protease
Inhibitor Cocktail (PI860, Sigma Chemical Co., St. Louis, MO) using an
ultrasonic cell disruptor. The homogenates were incubated for 2 h at
4 °C and centrifuged at 2080 g for 20 min at 4 °C. The supernatants
were removed and the pellets were suspended once again in the
same solution as described above, heated to 60 °C for 5 min and cen-
trifuged at 2080 g for 20 min at 4 °C. Protein was quantiﬁed using the
Bradford dye binding assay kit (BioAgency, São Paulo, SP, Brazil).
Twenty micrograms of protein extract obtained as above were
electrophoresed on a 10% SDS polyacrylamide gel containing 0.1%
gelatin (used as protein substrate) at 4 °C under non-reducing con-
ditions. After electrophoresis, the gel was washed twice, and then
gently shaken under 2.5% Triton X-100 for 30 min at room tempera-
ture to remove SDS. The gel was incubated overnight in a 50 mmol/L
Tris–HCl solution pH 7.4, containing 0.01 mol/L CaCl2, 0.1 mol/L NaCl
and 0.03% sodium azide at 37 °C. The gel was then stained with Coo-
massie Brilliant Blue (0.5% dye in 20% methanol and 10% acetic acid)
for 1 h. Unstained bands indicating gelatinolytic activity were seen
after slight destaining with 30% ethanol and 10% acetic acid. Quanti-
tative assessment of band intensity was done by densitometry using
the ImageJ image processing program (http://rsb.info.nih.gov/ij/).
All experiments were done in quadruplicate.Mas+/+
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Fig. 6. Sections of tricuspid valves from neonatal and adult Mas−/− and Mas+/+ mice and
analyzed at 10× magniﬁcation using polarizing ﬁlters adapted to a conventional light micro
was signiﬁcantly higher in AV valves (insets) of neonatal Mas−/−mouse hearts and in righ
tion microscopy is indicative of an increase in ﬁbrillar collagen. An increase was evident i
evident in sections of the ventricular wall (data not shown), suggesting that the increased a
ﬁgures of ﬁve different animals. Bar=50 μm.2.6. Echocardiographic analysis
Cardiac morphology and function in adult Mas+/+ and Mas−/−
mice (9–10 weeks old, n=5) were assessed noninvasively using a
high-frequency, high-resolution echocardiographic system consisting
of a VEVO 2100 ultrasound machine equipped with a 30–40 MHz
bifrequencial transducer (Visual Sonics, Toronto, Canada). The mice
were anesthetized with 5% isoﬂurane during 1 min for induction.
Anesthesia was sustained via a nose cone with 1.25% isoﬂurane.
The anterior chest was shaved and the mice were placed in supine
position on an imaging stage equipped with built-in electrocardio-
graphic electrodes for continuous heart rate monitoring and a heater
to maintain the body temperature at 37 °C. High-resolution images
were obtained in the right and left parasternal long and short axes
and apical orientations. Standard B-mode images of the heart and
pulsed Doppler images of the mitral and tricuspid inﬂow were ac-
quired. Left ventricular (LV) dimensions and wall thickness were
measured at the level of the papillary muscles in the left and right
parasternal short axis during the end-systole and end-diastole. LV
ejection fraction (EF), fractional shortening (FS) and mass were
measured. All the measurements and calculations were done in
accordance with the American Society of Echocardiography. The
following M-mode measurements were performed: LV internal di-
mensions at diastole and systole (LVIDD and LVIDS, respectively),
LV posterior wall dimensions at diastole and systole (LVPWD and
LVPWS, respectively) and interventricular septal dimensions atMas-/-
right ventricles of adult Mas−/− and Mas+/+ mice stained with picrosirius red and
scope. Based on observations with conventional microscopy, the total collagen content
t ventricles of adult Mas−/−mouse hearts. An increased birefringence with polariza-
n the AV valves of neonatal and adult Mas−/− mice. No increase in birefringence was
mount of collagen in the ventricle is present in themicroﬁbrillar form. Representative
37E. Gava et al. / Regulatory Peptides 175 (2012) 30–42diastole and systole (IVSDD and IVSDS, respectively). Based on
these parameters, end diastolic and end systolic LV volumes
(EDLVV and ESLVV, respectively), FS, EF, stroke volume (SV) and
cardiac output (CO) were calculated. Also, in the right parasternal
short axis view, bidimensional images from the right ventricle were ac-
quired for fractional area change (FAC) calculation.
2.7. Statistical analysis
Data are reported as mean±SEM. Statistical analyses were per-
formed using the MannWhitney test or Student's t test (echocardiog-
raphy). p values of 0.05 or less were considered signiﬁcant.
3. Results
First, we evaluated the presence of Mas in the different cardiac
chambers of mice. Immunoﬂuorescence-labeling and confocal mi-
croscopy demonstrated that, in addition to left ventricles [24], Mas
is expressed in the tricuspid valve, right ventricle and atria of adult
Mas+/+ mice (Fig. 1A, C and E). As expected, no expression of Mas
was observed in hearts of Mas−/− adult mice (Fig. 1B, D and F).
Fig. 2A shows immunostaining proﬁle of several ECM proteins in
the right ventricles and tricuspid valves of Mas+/+ and Mas−/− neo-
natal mice. Quantitative analysis of the level of immunoﬂuorescent
staining revealed that hearts fromMas−/− neonatal mice present sig-
niﬁcantly higher levels of collagen types I and III and ﬁbronectin in
right ventricles and tricuspid valves (Fig. 2B). In contrast, the level
of collagen type VI in Mas−/− neonatal mice was lower. A similar pat-
tern was observed in mitral valves of neonatal Mas−/−mice (Fig. 2B).
However, no signiﬁcant changes were viewed in the expression of
collagen types I, III and VI and ﬁbronectin in atria of Mas−/− neonatalCol I Col III
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Fig. 7. Immunoﬂuorescent localization of collagen types I, III and VI and ﬁbronectin in the rig
the right (B) and left ventricles (C) of adult AT2+/y and AT2−/y mice. Values are expressed asmice (Fig. 2B). To conﬁrm the protein expression proﬁle of ECM pro-
teins in hearts of Mas−/− neonatal mice, western blotting analysis
was performed. In agreement with the immunoﬂuorescence-labeling
ﬁndings, we found that the levels of collagen types I and III and ﬁbro-
nectin were higher while the level of collagen type VI was lower in
hearts of Mas−/− neonatal mice (Fig. 3).
A similar pattern of ECM protein expression was observed in
hearts of adult Mas−/− mice. Indeed, Mas deﬁcient adult mice pre-
sented signiﬁcantly higher levels of collagen types I and III and ﬁbro-
nectin and a lower level of collagen type VI in the right ventricle and
tricuspid valves (Fig. 4A and B). These changes were also detected in
mitral valves of adult Mas−/− mice (Fig. 4B). Nevertheless, no signif-
icant changes in the expression of these proteins were observed in
atria of adult Mas−/− mice (Fig. 4B). Importantly, these alterations
were conﬁrmed by western blotting analysis (Fig. 5). Of note, the
ﬁbrosis observed in Mas−/− mice was accompanied by a signiﬁcant
reduction in the right ventricular function, i.e. these mice presented
a reduced fractional area change (FAC) of the right ventricle. Also,
in keeping with a recent study [24], Mas−/− mice showed an im-
paired left ventricular function (Table 1).
Picrosirius red staining revealed that total collagen content pre-
sent in tricuspid valves of neonatal and adult Mas−/− mice, as well
as in right ventricles of adult Mas−/−mice appears to be signiﬁcantly
higher when compared with Mas+/+ mice (Fig. 6). An increased bire-
fringence pattern observed when polarization microscopy was used
indicates that more ﬁbrous collagen was present. Such an increase
was evident in tricuspid valves of neonatal and adult Mas−/− mice
(Fig. 6). Although sections of the right ventricular wall were stained
more intensely with picrosirius red when they were observed with
conventional microscopy (Fig. 6), no signiﬁcant increases in polariza-
tion were evident (data not shown). Together, these results suggestCol VIFN
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38 E. Gava et al. / Regulatory Peptides 175 (2012) 30–42that the increased amount of collagen observed with conventional
picrosirius red staining, as well as with immunostaining for collagen
types I and III, is present as microﬁbrillar material.
Because AT2 receptors have been suggested to be involved in some
Ang-(1-7) effects, we evaluated the expression of ECM proteins in
hearts of AT2 deﬁcient mice. Fig. 7A shows the immunostaining pro-
ﬁle of the levels of collagen types I, III and VI and ﬁbronectin in
right ventricles of AT2+/y and AT2−/y adult mice. Quantitative analysis
of the level of immunoﬂuorescent staining demonstrated that right
(Fig. 7B) and left (Fig. 7C) ventricles from AT2−/y mice present no sig-
niﬁcant alterations in the expression of these proteins as compared
with AT2+/y mice.
It is well-known that MMPs have a major role in ECM degradation.
Thus, our next objective was to investigate if MMPs were involved in
the deposition of ECM proteins in hearts of Mas−/− mice. Deﬁciency
of Mas induced a signiﬁcant reduction in the level of the active form
of MMP-2 in neonate hearts (Fig. 8A). In contrast, no signiﬁcant alter-
ation was observed in the level of the active form of MMP-9 in hearts
of neonate Mas−/− mice (Fig. 8B). In adult hearts, western blotting
analysis detected the presence of a single MMP-2 band in the gel
whose density was lower in Mas−/− mice (Fig. 8C). Furthermore,
the level of the active form of MMP-9 was signiﬁcantly lower in
Mas deﬁcient mice (Fig. 8D).
As observed in Fig. 9A, gelatinolytic activity of the active form of
MMP-2 (62 kDa) and its precursor form (68 kDa) were detected
only in neonate hearts. Although the active form of MMP-9
(82 kDa) was detected on zymographs in both neonate and adult
hearts (Fig. 9A), no signiﬁcant differences were observed in metallo-
proteinase activity between the groups (Fig. 9B–E).Mas+/+ Mas-/-
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heart (A). Active form of MMP-9 in neonate heart (B). A single band was detected in the im
right ventricles (D). Data are shown as the SEM. *pb0.05.In order to investigate the potential involvement of protein ki-
nases in ECM deposition, the levels of phosphorylated ERK1/2 and
p38 protein expression were evaluated in hearts of neonatal and
adult Mas−/− mice. We observed that the levels of p-ERK1/2 and p-
p38 were higher in hearts of both neonatal and adult Mas−/− mice
when compared with control animals (Fig. 10).4. Discussion
We have previously described that genetic deletion of Mas leads
to a marked impairment of cardiac function [24]. Systolic tension,
+dT/dt and −dT/dt were signiﬁcantly lower in isolated hearts of
Mas-deﬁcient mice. Echocardiographic measurements revealed a
lower fractional shortening, posterior wall thickness in systole and a
higher left ventricular end-systolic dimension. In addition, Mas−/−
mice presented a higher coronary perfusion pressure compared
with Mas+/+ mice. These alterations appear to be caused, at least
partially, by severe alterations in collagen protein expression in left
ventricles [24]. In the current study, we extended the observation
that Mas is a key modulator of several ECM proteins in mouse hearts.
Neonatal and adult Mas knockout mice showed signiﬁcantly higher
levels of collagen types I and III and ﬁbronectin in both right ventricle
and AV valves. In contrast, the level of collagen type VI in these tis-
sues was lower in Mas−/− mice. In agreement with our data, many
studies have demonstrated that Ang-(1-7) induces antiproliferative
and anti-ﬁbrotic effects by acting through the Mas receptor [12–14].
Interestingly, the alterations in cardiac expression of ECM proteins
were not observed in the atria of neonatal or adult Mas−/− mice,Mas+/+ Mas-/-
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stricted to speciﬁc heart regions.
Previous biochemical and molecular studies have been limited to
the description of the expression of Mas in the whole heart [24,26].
Here, we showed by immunoﬂuorescence-labeling the precise distri-
bution of Mas in different areas of the heart. Mas was presented in the
right ventricle, AV valves and atria. Thus, the lack of effects of genetic
deletion of Mas in atria could not be attributed to the absence of this
receptor in these chambers.
Surprisingly, in contrast to collagen types I and III, the levels of
collagen type VI were decreased in ventricles and AV valves of neo-
natal and adult Mas−/− mice, indicating that Mas selectively regu-
lates the expression of speciﬁc ECM proteins in mouse hearts.
Collagen type VI forms a microﬁbrillar extracellular network that is
thought to function as an elastic bridge between cell surfaces or
basement membranes and the structural ECM scaffold. It is possible
that collagen type VI is important for maintaining an appropriate re-
lationship between cells and ECM in cardiac structures exposed to
variable states of wall stress. Heart structures must acutely regulate
tensile support in response to alterations in the cardiac cycle [27].
Decreased amounts of collagen type VI may therefore adversely af-
fect cardiac function.
Of note, neonatal mice presented a similar pattern of ECM protein
expression as observed in adult mice. These results might suggest
that the primary cause of the structural and functional disturbances
seen in hearts of adult mice is due to changes in cardiac expression
of ECM proteins and not due to chronic adaptative alterations. Indeed,C57BL6Mas−/−mice presented normal blood pressure as assessed by
intra-arterial catheter measurements [24,28]. Furthermore, it was
found that Mas−/− mice are healthy, grow normally, display no dif-
ference in drinking behavior and show no obvious developmental
abnormalities [29]. However, whether this possibility is true remains
to be elucidated and warrants further investigations. This includes,
but is not limited to, evaluation of shift in elastic versus ﬁbrous
ECM components, changes that may occur in heart function from
neonatal to adulthood and associations between heart function and
expression of speciﬁc ECM components.
In certain circumstances, and in some tissues, AT2 receptors ap-
pear to be involved in the Ang-(1-7) effects [30]. Furthermore,
physical interaction between Mas and AT2 in selected tissues such
as the heart has been suggested as a putative mechanism for Ang-
(1-7) actions [31]. In order to investigate the participation of AT2
receptors in the anti-trophic and anti-ﬁbrotic actions of the Ang-
(1-7), we compared the effects of genetic deletion of Mas and AT2
receptors on the ECM protein expression in the heart. In contrast
to the marked ﬁbrotic pattern observed in Mas−/− mice, no signif-
icant alterations in the levels of collagen types I, III and VI and ﬁbro-
nectin were observed in AT2−/y mice. In agreement with this data,
Ichihara et al. [32] also failed to demonstrate any signiﬁcant differ-
ence in the collagen deposition between AT2−/y and AT2+/y mice in
normal conditions. These ﬁndings suggest that the modulation of ECM
proteins by Ang-(1-7) is AT2-indepentent. Of note, it has been recently
demonstrated that the anti-hypertrophic effect of Ang-(1-7) in cardio-
myocytes is also independent of AT2 receptors [33].
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40 E. Gava et al. / Regulatory Peptides 175 (2012) 30–42The composition of the extracellular matrix, a complex network of
structural proteins including collagen types I and III, provides archi-
tectural support for the muscle cells and plays an important role in
myocardial function [34]. Collagen type VI is a major microﬁbrillar
component of extracellular matrices and is predicted to play a key
role in the maintenance of tissue integrity by providing a structural
link between different components of connective tissues, basement
membranes, and cells binding to collagen type I, collagen type III and
other matrix components. A number of studies have shown changes
in the accumulation, composition, or organization of these interstitial
collagens, including types I, III, and VI, during cardiac development
and disease. The accumulation ofmyocardial collagen lead to interstitial
and perivascularﬁbrosiswhich has been correlatedwith left ventricular
early diastolic and systolic dysfunction [6,35,36]. MMP-2 and MMP-9
are expressed by a multitude of cell types including cardiac myocytes
and ﬁbroblasts. It was reported that both enzymes are highly upregu-
lated in hypertrophic and failing hearts and they have been implicated
in the progression of ventricular dilatation and the development of
heart failure. MMP-2 and MMP-9 degrade various types of collagen,
ﬁbronectin, and others proteins that are accumulating in the dam-
aged myocardium undergoing ﬁbrosis [37]. Thus, we selected these
two metalloproteinases to correlate them to the alterations in the
ECM proteins evaluated in our study. In addition, the deposition of
ECM proteins in the heart depends on the balance between the syn-
thesis of these proteins and their degradation by metalloproteinases
[38]. There is little data available concerning the effects of Ang-(1-7)
and its receptor Mas on the biosynthesis of ECM proteins or on the
activity of metalloproteinases. We observed that the level of the ac-
tive form of MMP-2 in hearts of neonatal Mas−/− mice is lower than
in Mas+/+ mice while the active form of MMP-9 is not altered. Also,
the level of MMP-2 and of the active form of MMP-9 were signiﬁcantly
lower in adult Mas−/− hearts. Altogether, these ﬁndings suggest that
the pro-ﬁbrotic proﬁle observed in Mas−/− mice might be related toalterations in the expression of metalloproteinases. However, it is
important to note that although we were able to detect the presence
of MMP-2 and MMP-9 in the heart, the changes observed in the
levels of these MMPs were not accompanied by modiﬁcations in
their activities. Indeed, both western blot and gelatin zymography
can be used to determine the presence of MMPs in the tissue. Howev-
er, the western blot shows the presence of MMPs while zymography
determines the activity of MMPs.
The lack of effects observed in the MMP activities in Mas−/−mice
might be explained by a limitation of the technique. Zymography uses
gelatin as a substrate which is composed of denatured collagen. In
addition to their activities in collagen degradation, MMP-2 and MMP-
9 act in other components of the ECM, such as elastin, ﬁbronectin and
laminin [39]. MMP-2 also acts on decorinwhich is an important compo-
nent of the ECM [40]. Thus, the divergent results observed between
western blot and zymography may be related to the actions of MMP-2
and MMP-9 on other substrates than collagen. Moreover, low concen-
tration of MMPs in our samples might contribute to the lack of effects
observed in theMMP activities. Similarly, the discrepancy observed be-
tween ECMdevelopment and the changes inMMP-9 protein expression
whenpassing fromneonatal to adult lifemay be related to the actions of
MMP-9 in other substrates than the proteins evaluated in our study. In
fact, MMP-9may act in other components of the ECM and has high sub-
strate afﬁnity for basement membrane proteins [41–44].
A variety of signal transduction pathways have been shown to be
involved in the regulation of ECM deposition/degradation, including
p38 and ERK1/2 MAP kinase pathways [45–47]. In the present study,
we demonstrated that the active, phosphorylated forms of p38 and
ERK1/2 are increased in neonatal and adult Mas−/− mice hearts.
These data are in agreement with previous studies demonstrating that
Ang-(1-7) is able to inhibit MAP kinase phosphorylation in different
tissues [48–51]. These ﬁndings suggest that the Ang-(1-7)/Mas axis
could be involved in the regulation of the synthesis and/or
41E. Gava et al. / Regulatory Peptides 175 (2012) 30–42degradation of collagen and non-collagen proteins by acting in the
regulation of the MAP kinase activity. One may argue that, because
Ang-(1-7) at pharmacological concentrations can bind and, eventu-
ally, activate AT1 receptors [52], this peptide may change the AT1-
mediated stimulation of the ERK/MAPK pathway in the absence of
Mas. However, this possibility is unlikely since a recent study has
reported that the plasma levels of Ang II and Ang I and the plasma
renin activity are similar in both Mas+/+ and Mas−/− mice [53].
Although these data do not exclude this hypothesis, they are an in-
dicative that the stimulation of ERK/MAPK observed in our study is
not due to the action of Ang-(1-7) on AT1 receptors. Further exper-
iments are obviously needed to conﬁrm this possibility.5. Conclusions
In summary, our data suggest that Mas is involved in the selective
regulation of the expression of speciﬁc ECM proteins within both ven-
tricular myocardium and AV valves. The proﬁle observed may con-
tribute to the decreased cardiac performance viewed in Mas−/−mice.Acknowledgments
This work was supported in part by CNPq-PRONEX (Conselho
Nacional de Desenvolvimento Cientíﬁco e Tecnológico — Programa
de Grupos de Excelência), FAPEMIG (Fundação de Amparo à Pesquisa
do Estado de Minas Gerais) and CAPES (Coordenação de Aperfeiçoa-
mento de Pessoal de Nível Superior). The Zeiss confocal microscope
is located in the Centro de Microscopia (CEMEL), Instituto de Ciên-
cias Biológicas, Universidade Federal de Minas Gerais.References
[1] Robinson TF, Cohen-Gould L, Factor SM. Skeletal framework of mammalian heart
muscle. Arrangement of inter- and pericellular connective tissue structures. Lab
Invest 1983;49:482–98.
[2] Weber KT. Cardiac interstitium in health and disease: the ﬁbrillar collagen net-
work. J Am Coll Cardiol 1989;13:1637–52.
[3] Burlew BS, Weber KT. Connective tissue and the heart. Functional signiﬁcance and
regulatory mechanisms. Cardiol Clin 2000;18:435–42.
[4] Gonzalez A, Lopez B, Querejeta R, Diez J. Regulation of myocardial ﬁbrillar collagen
by angiotensin II. A role in hypertensive heart disease? J Mol Cell Cardiol 2002;34:
1585–93.
[5] Weber KT, Clark WA, Janicki JS, Shroff SG. Physiologic versus pathologic hypertrophy
and the pressure-overloaded myocardium. J Cardiovasc Pharmacol 1987;10(Suppl 6):
S37–50.
[6] Villarreal FJ, Dillmann WH. Cardiac hypertrophy-induced changes in mRNA levels
for TGF-beta 1, ﬁbronectin, and collagen. Am J Physiol 1992;262:H1861–6.
[7] Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult
rat cardiac ﬁbroblasts: response to angiotensin II and aldosterone. J Mol Cell Car-
diol 1994;26:809–20.
[8] Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardio-
vascular and renal diseases. Circ Res 1998;83:1182–91.
[9] Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, et al.
Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor
Mas. Proc Natl Acad Sci U S A 2003;100:8258–63.
[10] Freeman EJ, Chisolm GM, Ferrario CM, Tallant EA. Angiotensin-(1-7) inhibits vas-
cular smooth muscle cell growth. Hypertension 1996;28:104–8.
[11] Strawn WB, Ferrario CM, Tallant EA. Angiotensin-(1-7) reduces smooth muscle
growth after vascular injury. Hypertension 1999;33:207–11.
[12] Machado RD, Santos RA, Andrade SP. Opposing actions of angiotensins on angio-
genesis. Life Sci 2000;66:67–76.
[13] Tallant EA, Ferrario CM, Gallagher PE. Angiotensin-(1-7) inhibits growth of cardiac
myocytes through activation of the Mas receptor. Am J Physiol Heart Circ Physiol
2005;289:H1560–6.
[14] Iwata M, Cowling RT, Gurantz D, Moore C, Zhang S, Yuan JX, et al. Angiotensin-(1-7)
binds to speciﬁc receptors on cardiac ﬁbroblasts to initiate antiﬁbrotic and anti-
trophic effects. Am J Physiol Heart Circ Physiol 2005;289:H2356–63.
[15] Loot AE, Roks AJ, Henning RH, Tio RA, Suurmeijer AJ, van Boomsma F, et al. Angio-
tensin-(1-7) attenuates the development of heart failure after myocardial infarc-
tion in rats. Circulation 2002;105:1548–50.
[16] Ferreira AJ, Jacoby BA, Araujo CA, Macedo FA, Silva GA, Almeida AP, et al. The
nonpeptide angiotensin-(1-7) receptor Mas agonist AVE-0991 attenuates
heart failure induced by myocardial infarction. Am J Physiol Heart Circ Physiol
2007;292:H1113–9.[17] Ferreira AJ, Oliveira TL, Castro MC, Almeida AP, Castro CH, Caliari MV, et al. Isopro-
terenol-induced impairment of heart function and remodeling are attenuated by
the nonpeptide angiotensin-(1-7) analogue AVE 0991. Life Sci 2007;81:916–23.
[18] Grobe JL, Mecca AP, Mao H, Katovich MJ. Chronic angiotensin-(1-7) prevents car-
diac ﬁbrosis in DOCA-salt model of hypertension. Am J Physiol Heart Circ Physiol
2006;290:H2417–23.
[19] Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM, et al. Prevention
of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol
Heart Circ Physiol 2007;292:H736–42.
[20] Der Sarkissian S, Grobe JL, Yuan L, Narielwala DR, Walter GA, Katovich MJ, et al.
Cardiac overexpression of angiotensin converting enzyme 2 protects the heart
from ischemia-induced pathophysiology. Hypertension 2008;51:712–8.
[21] Ferreira AJ, Shenoy V, Yamazato Y, Sriramula S, Francis J, Yuan L, et al. Evidence for
angiotensin-converting enzyme 2 as a therapeutic target for the prevention of
pulmonary hypertension. Am J Respir Crit Care Med 2009;179:1048–54.
[22] Yamazato Y, Ferreira AJ, Hong KH, Sriramula S, Francis J, Yamazato M, et al. Pre-
vention of pulmonary hypertension by Angiotensin-converting enzyme 2 gene
transfer. Hypertension 2009;54:365–71.
[23] Shenoy V, Ferreira AJ, Qi Y, Fraga-Silva RA, Diez-Freire C, Dooies A, et al. The
angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardio-
pulmonary protection against lung ﬁbrosis and pulmonary hypertension. Am J
Respir Crit Care Med 2010;182:1065–72.
[24] Santos RA, Castro CH, Gava E, Pinheiro SV, Almeida AP, Paula RD, et al. Impairment
of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout
mice. Hypertension 2006;47:996–1002.
[25] Junqueira LC, Bignolas G, Brentani RR. Picrosirius staining plus polarization mi-
croscopy, a speciﬁc method for collagen detection in tissue sections. Histochem
J 1979;11:447–55.
[26] Metzger R, Bader M, Ludwig T, Berberich C, Bunnemann B, Ganten D. Expression
of the mouse and rat mas proto-oncogene in the brain and peripheral tissues.
FEBS Lett 1995;357:27–32.
[27] Klewer SE, Krob SL, Kolker SJ, Kitten GT. Expression of type VI collagen in the
developing mouse heart. Dev Dyn 1998;211:248–55.
[28] Walther T, Wessel N, Kang N, Sander A, Tschope C, Malberg H, et al. Altered heart
rate and blood pressure variability in mice lacking the Mas protooncogene. Braz J
Med Biol Res 2000;33:1–9.
[29] Walther T, Balschun D, Voigt JP, Fink H, Zuschratter W, Birchmeier C, et al. Sus-
tained long term potentiation and anxiety in mice lacking the Mas protoonco-
gene. J Biol Chem 1998;273:11867–73.
[30] Walters PE, Gaspari TA, Widdop RE. Angiotensin-(1-7) acts as a vasodepressor
agent via angiotensin II type 2 receptors in conscious rats. Hypertension 2005;45:
960–6.
[31] Castro CH, Santos RA, Ferreira AJ, Bader M, Alenina N, Almeida AP. Evidence for a
functional interaction of the angiotensin-(1-7) receptor Mas with AT1 and AT2
receptors in the mouse heart. Hypertension 2005;46:937–42.
[32] Ichihara S, Senbonmatsu T, Price Jr E, Ichiki T, Gaffney FA, Inagami T. Angiotensin
II type 2 receptor is essential for left ventricular hypertrophy and cardiac ﬁbrosis
in chronic angiotensin II-induced hypertension. Circulation 2001;104:346–51.
[33] Flores-Munoz M, Smith NJ, Haggerty C, Milligan G, Nicklin SA. Angiotensin1-9
antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin
type 2 receptor. J Physiol 2011;589:939–51.
[34] Weber KT, Sun Y, Katwa LC, Cleutjens JP, Zhou G. Connective tissue and repair in
the heart. Potential regulatory mechanisms. Ann N Y Acad Sci 1995;752:286–99.
[35] Reddi AS. Collagen metabolism in the myocardium of normal and diabetic rats.
Exp Mol Pathol 1988;48:236–43.
[36] Tschope C, Walther T, Koniger J, Spillmann F, Westermann D, Escher F, et al. Pre-
vention of cardiac ﬁbrosis and left ventricular dysfunction in diabetic cardiomy-
opathy in rats by transgenic expression of the human tissue kallikrein gene.
FASEB J 2004;18:828–35.
[37] Panek AN, Bader M. Matrix reloaded: the matrix metalloproteinase paradox.
Hypertension 2006;47:640–1.
[38] McAnulty RJ, Laurent GJ. Collagen synthesis and degradation in vivo. Evidence for
rapid rates of collagen turnover with extensive degradation of newly synthesized
collagen in tissues of the adult rat. Coll Relat Res 1987;7:93–104.
[39] Chow AK, Cena J, Schulz R. Acute actions and novel targets of matrix metallopro-
teinases in the heart and vasculature. Br J Pharmacol 2007;152:189–205.
[40] Imai K, Hiramatsu A, Fukushima D, Pierschbacher MD, Okada Y. Degradation
of decorin by matrix metalloproteinases: identiﬁcation of the cleavage sites,
kinetic analyses and transforming growth factor-beta1 release. Biochem J
1997;322(Pt 3):809–14.
[41] Parsons SL, Watson SA, Brown PD, Collins HM, Steele RJ. Matrix metalloprotei-
nases. Br J Surg 1997;84:160–6.
[42] Nagase H, Woessner Jr JF. Matrix metalloproteinases. J Biol Chem 1999;274:
21491–4.
[43] Woessner Jr JF. Matrix metalloproteinases and their inhibitors in connective tis-
sue remodeling. FASEB J 1991;5:2145–54.
[44] Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal
physiology. Genes Dev 2000;14:2123–33.
[45] Booz GW, Baker KM. Molecular signalling mechanisms controlling growth and
function of cardiac ﬁbroblasts. Cardiovasc Res 1995;30:537–43.
[46] Gao X, He X, Luo B, Peng L, Lin J, Zuo Z. Angiotensin II increases collagen I expres-
sion via transforming growth factor-beta1 and extracellular signal-regulated ki-
nase in cardiac ﬁbroblasts. Eur J Pharmacol 2009;606:115–20.
[47] Touyz RM, He G, El Mabrouk M, Schiffrin EL. p38 Map kinase regulates vascular
smooth muscle cell collagen synthesis by angiotensin II in SHR but not in WKY.
Hypertension 2001;37:574–80.
42 E. Gava et al. / Regulatory Peptides 175 (2012) 30–42[48] Su Z, Zimpelmann J, Burns KD. Angiotensin-(1-7) inhibits angiotensin II-stimulated
phosphorylation of MAP kinases in proximal tubular cells. Kidney Int 2006;69:
2212–8.
[49] Giani JF, Gironacci MM, Munoz MC, Turyn D, Dominici FP. Angiotensin-(1-7) has
a dual role on growth-promoting signalling pathways in rat heart in vivo by
stimulating STAT3 and STAT5a/b phosphorylation and inhibiting angiotensin
II-stimulated ERK1/2 and Rho kinase activity. Exp Physiol 2008;93:570–8.
[50] SampaioWO,Henrique de Castro C, Santos RA, Schiffrin EL, Touyz RM. Angiotensin-(1-
7) counterregulates angiotensin II signaling in human endothelial cells. Hypertension
2007;50:1093–8.[51] Gava E, Samad-Zadeh A, Zimpelmann J, Bahramifarid N, Kitten GT, Santos RA, et al.
Angiotensin-(1-7) activates a tyrosine phosphatase and inhibits glucose-induced
signalling in proximal tubular cells. Nephrol Dial Transplant 2009;24:1766–73.
[52] Clark MA, Tallant EA, Diz DI. Downregulation of the AT1A receptor by pharmaco-
logic concentrations of Angiotensin-(1-7). J Cardiovasc Pharmacol 2001;37:
437–48.
[53] Rabelo LA, Xu P, Todiras M, Samaio WO, Buttgereit J, Bader M, et al. Ablation of
angiotensin (1-7) receptor Mas in C57Bl/6 mice causes endothelial dysfunction.
J Am Soc Hypertens 2008;2:418–24.
